WO 2004/085628 PCT/GB2004/001398

36

1	CLAIMS		
2			
3	1.	A method of selecting a strain of lactic acid-	
4		utilising bacteria, which method comprises the	
5		steps of:	
6			
7		a) providing a bacterial culture from a human	
8		<pre>faecal sample;</pre>	
9		b) selecting a single colony of bacteria;	
10		c) growing said colony in a suitable medium	
11		containing lactic acid; and	
12		d) selecting a strain of bacteria consuming	
13		relatively large amounts of lactic acid,	
14			
15		all of the above steps being conducted under	
16		anaerobic conditions.	
17			
18	2.	The method as claimed in Claim 1 wherein at	
19		least 10mM of lactic acid is consumed during	
20		growth into the stationary phase per 24 hours	
21		at 37°C in YCFALG or YCFAL medium.	
22			
23	3.	The method as claimed in either one of Claims 1	
24		and 2 wherein said method comprises the	
25		additional step of:	
26			
27		e) selecting a strain of bacteria producing	
28		relatively large quantities of butyric	
29		acid.	
30			
31	4.	The method as claimed in Claim 3 wherein at	
32		least 10mM butyric acid is produced during	

WO 2004/085628 PCT/GB2004/001398

37

		•
1		bacterial growth into the stationary phase per
2		24 hours at 37°C in YCFALG or YCFAL medium.
3		
4	5.	The method as claimed in any one of Claims 1 to
5		4 wherein said lactic acid is a mixture of D
6		and L isomers of lactic acid.
7		
8	6.	Anaerostipes caccae strain L1-92 deposited at
9		NCIMB under No. 13801 <sup>T</sup> .
10		
11	7.	Clostridium indolis bacterial strain Ss2/1
12		deposited at NCIMB under No. 41156.
13		
14	8.	Eubacterium hallii strain SM 6/1 deposited at
15		NC1MB under No. 41155.
16		
17	9.	A lactic acid utilising bacterium having a 16S
18		rRNA gene sequence with at least 95% homology
19		to one of the sequences shown in Fig. 1.
20		
21	10.	A bacterial strain as claimed in any one of
22		Claims 6 to 9 for use as a medicament to treat
23		lactic acid induced disorders or as a
24		foodstuff.
25		
26	11.	A bacterial strain as claimed in Claim 10 for
27		use as a medicament to treat lactic-acidosis,
28		short bowel syndrome or inflammatory bowel
29		disease.
30		
31	12.	A method to promote butyric acid formation in
32		the intestine of a mammal, said method

WO 2004/085628 PCT/GB2004/001398

38

1		comprising the administration of a
2		therapeutically effective dose of at least one
3		of the strains of bacteria as claimed in any
4		one of Claims 6 to 9.
5		
6	13.	The method of Claim 12 wherein said bacteria is
7		administered as a foodstuff or as a
8		suppository.
9		
LO	14.	A method for treating a disease associated with
L1		a high dosage of lactic acid, which method
12		comprises the administration of a.
L3		therapeutically effective dose of at least one
14		strain of live lactic acid utilising bacteria
L5		as claimed in any one of Claims 6 to 9.
16		
L 7	15.	The method of Claim 14 wherein said disease is
18		lactic-acidosis, short bowel syndrome or
19		inflammatory bowel disease.
20		
21	16.	The method of either one of Claims 14 and 15
22		wherein said bacteria is Anaerostipes caccae.
23		
24	17.	A prophylactic method to reduce the incidence
25		or severity of colorectal cancer or colitis in
26		mammals caused in part by high lactic acid and
27		low butyric acid concentrations, which method
28		comprises the administration of a
29		therapeutically effective dose of at least one
30		strain of live lactic acid utilising bacteria
31		as claimed in any one of Claims 6 to 9.
32		

WO 2004/085628

39

PCT/GB2004/001398

1	18.	The method of Claim 17 wherein said bacteria is
2		Anaerostipes caccae.
3		
4	19.	A probiotic composition comprising a live
5		bacterial strain as claimed in any one of
6		Claims 6 to 9, in combination with live lactic
7		acid producing bacteria.
8		
9	20.	The composition as claimed in Claim 19 wherein
10		said lactate acid producing bacteria is
11		Lactobacillus spp, Bifidobacterium spp or a
12		mixture thereof.
13		
14	21.	The method of either one of Claims 19 and 20
15		wherein said bacteria is Anaerostipes caccae.
16		
17	22.	The composition as claimed in any one of Claims
18		19 to 21 further containing other additives or
19		growth enhancing supplements.